Loss of TFF1 is associated with activation of NF-κB-mediated inflammation and gastric neoplasia in mice and humans

Journal of Clinical Investigation

Volumn 121, Issue 5, 2011, Pages 1753-1767

  Soutto, Mohammed ^a   Belkhiri, Abbes ^a   Piazuelo, M Blanca ^a   Schneider, Barbara G ^a   Peng, DunFa ^a   Jiang, Aixiang ^a   Washington, M Kay ^a   Kokoye, Yasin ^a   Crowe, Sheila E ^b   Zaika, Alexander ^a,c   Correa, Pelayo ^a   Peek Jr , Richard M ^a   El Rifai, Wael ^a,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN; PROTEIN TFF1; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DYSPLASIA; FEMALE; GASTRITIS; HUMAN; HUMAN TISSUE; HYPERPLASIA; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYLORUS; STOMACH ADENOCARCINOMA; STOMACH ANTRUM; STOMACH CARCINOGENESIS; STOMACH MUCOSA;

ANIMALS; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HUMANS; I-KAPPA B PROTEINS; INFLAMMATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDES; PHOSPHORYLATION; STOMACH; STOMACH NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEINS;

EID: 79955509042     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI43922     Document Type: Article

References (47)

1. Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988;48(13):3554-3560.
2. Thim L, May FE. Structure of mammalian trefoil factors and functional insights. Cell Mol Life Sci. 2005;62(24):2956-2973. (Pubitemid 43004748)
3. Ribieras S, Tomasetto C, Rio MC. The pS2/TFF1 trefoil factor, from basic research to clinical applications. Biochim Biophys Acta. 1998;1378(1):F61-F77. (Pubitemid 28381126)
4. Corte MD, et al. Cytosolic levels of TFF1/pS2 in breast cancer: Their relationship with clinical-pathological parameters and their prognostic significance. Breast Cancer Res Treat. 2006;96(1):63-72.
5. Rio MC, et al. Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa. Science. 1988;241(4866):705-708.
6. Taupin D, Pedersen J, Familari M, Cook G, Yeomans N, Giraud AS. Augmented intestinal trefoil factor (TFF3) and loss of pS2 (TFF1) expression precedes metaplastic differentiation of gastric epithelium. Lab Invest. 2001;81(3):397-408. (Pubitemid 32245071)
7. Carvalho R, et al. Loss of heterozygosity and promoter methylation, but not mutation, may underlie loss of TFF1 in gastric carcinoma. Lab Invest. 2002; 82(10):1319-1326. (Pubitemid 35191535)
8. Katoh M. Trefoil factors and human gastric cancer (review). Int J Mol Med. 2003;12(1):3-9.
9. McChesney PA, et al. Cofactor of BRCA1: a novel transcription factor regulator in upper gastrointestinal adenocarcinomas. Cancer Res. 2006; 66(3):1346-1353. (Pubitemid 43259913)
10. Park WS, et al. Mapping of a new target region of allelic loss at 21q22 in primary gastric cancers. Cancer Lett. 2000;159(1):15-21.
11. Ribieras S, Lefebvre O, Tomasetto C, Rio MC. Mouse Trefoil factor genes: genomic organization, sequences and methylation analyses. Gene. 2001; 266(1-2):67-75. (Pubitemid 32268657)
12. Fujimoto J, Yasui W, Tahara H, Tahara E, Kudo Y, Yokozaki H. DNA hypermethylation at the pS2 promoter region is associated with early stage of stomach carcinogenesis. Cancer Lett. 2000;149(1-2):125-134. (Pubitemid 30100568)
13. Tomita H, et al. Inhibition of gastric carcinogenesis by the hormone, gastrin, is mediated by suppression of TFF1 epigenetic silencing [published online ahead of print November 25, 2010]. Gastroenterology. doi: 10.1053/j.gastro.2010.11.037.
14. Park WS, et al. Somatic mutations of the trefoil factor family 1 gene in gastric cancer. Gastroenterology. 2000;119(3):691-698.
15. Sankpal NV, Mayo MW, Powell SM. Transcriptional repression of TFF1 in gastric epithelial cells by CCAAT/enhancer binding protein-beta. Biochim Biophys Acta. 2005;1728(1-2):1-10. (Pubitemid 40409950)
16. Calnan DP, Westley BR, May FE, Floyd DN, March-bank T, Playford RJ. The trefoil peptide TFF1 inhibits the growth of the human gastric adenocarcinoma cell line AGS. J Pathol. 1999;188(3):312-317. (Pubitemid 29317776)
17. Lefebvre O, et al. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science. 1996;274(5285):259-262. (Pubitemid 26353205)
18. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336(15):1066-1071. (Pubitemid 27163860)
19. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell. 2006;124(4):823-835. (Pubitemid 43261455)
20. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006; 441(7092):431-436. (Pubitemid 44050137)
21. Karin M. The IkappaB kinase - a bridge between inf lammation and cancer. Cell Res. 2008; 18(3):334-342. (Pubitemid 351333897)
22. Greten FR, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118(3):285-296. (Pubitemid 39061110)
23. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5(10):749-759. (Pubitemid 41400849)
24. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest. 2005;115(10):2625-2632. (Pubitemid 41434385)
25. Pikarsky E, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431(7007):461-466. (Pubitemid 39329586)
26. Yan F, Polk DB. Disruption of NF-kappaB signalling by ancient microbial molecules: novel therapies of the future? Gut. 2010;59(4):421-426.
27. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell. 1996;87(1):13-20.
28. Li H, Lin X. Positive and negative signaling components involved in TNFalpha-induced NF-kappaB activation. Cytokine. 2008;41(1):1-8. (Pubitemid 50012147)
29. Häcker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE. 2006; 2006(357):re13.
30. Shu HB, Takeuchi M, Goeddel DV. The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex. Proc Natl Acad Sci U S A. 1996;93(24):13973-13978.
31. Hanby AM, Poulsom R, Singh S, Elia G, Jeffery RE, Wright NA. Spasmolytic polypeptide is a major antral peptide: distribution of the trefoil peptides human spasmolytic polypeptide and pS2 in the stomach. Gastroenterology. 1993;105(4):1110-1116. (Pubitemid 23281500)
32. Henry JA, Bennett MK, Piggott NH, Levett DL, May FE, Westley BR. Expression of the pNR-2/pS2 protein in diverse human epithelial tumours. Br J Cancer. 1991;64(4):677-682.
33. Westley BR, Griffin SM, May FE. Interaction between TFF1, a gastric tumor suppressor trefoil protein, and TFIZ1, a brichos domain-containing protein with homology to SP-C. Biochemistry. 2005; 44(22):7967-7975. (Pubitemid 40776657)
34. Baron JA, Sandler RS. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med. 2000;51:511-523. (Pubitemid 30216052)
35. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. J Clin Invest. 2007;117(1):60-69. (Pubitemid 46048450)
36. Schwartsburd PM. Age-promoted creation of a pro-cancer microenvironment by inflammation: pathogenesis of dyscoordinated feedback control. Mech Ageing Dev. 2004;125(9):581-590. (Pubitemid 39371152)
37. Murphy G, et al. Association of gastric disease with polymorphisms in the inflammatory-related genes IL-1B, IL-1RN, IL-10, TNF and TLR4. Eur J Gastroenterol Hepatol. 2009;21(6):630-635.
38. Machado JC, et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology. 2003; 125(2):364-371. (Pubitemid 36929416)
39. Tu S, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell. 2008;14(5):408-419.
40. Mauro C, Zazzeroni F, Papa S, Bubici C, Franzoso G. The NF-kappaB transcription factor pathway as a therapeutic target in cancer: methods for detection of NF-kappaB activity. Methods Mol Biol. 2009; 512:169-207.
41. Katoh M. AP1- and NF-kappaB-binding sites conserved among mammalian WNT10B orthologs elucidate the TNFalpha-WNT10B signaling loop implicated in carcinogenesis and adipogenesis. Int J Mol Med. 2007;19(4):699-703.
42. Koike T, et al. Up-regulation of TFF1 (pS2) expression by TNF-alpha in gastric epithelial cells. J Gastroenterol Hepatol. 2007;22(6):936-942. (Pubitemid 46911025)
43. Irizarry RA, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249-264.
44. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3.
45. R Development Core Team. R: A Language And Environment For Statistical Computing. Vol. 1. Vienna, Austria: R Foundation for Statistical Computing; 2009.
46. El-Rifai W, et al. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res. 2002; 62(23):6823-6826. (Pubitemid 35424067)
47. Mukherjee K, et al. Dopamine and cAMP regulated phosphoprotein MW 32 kDa is overexpressed in early stages of gastric tumorigenesis. Surgery. 2010; 148(2):354-363.